Profile data is unavailable for this security.
About the company
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
- Revenue in USD (TTM)44.56bn
- Net income in USD6.70bn
- Incorporated1960
- Employees125.00k
- LocationThermo Fisher Scientific Inc168 Third AvenueWALTHAM 02451United StatesUSA
- Phone+1 (781) 622-1000
- Fax+1 (781) 622-1207
- Websitehttps://corporate.thermofisher.com/us/en/index.html
More ▼
Mergers & acquisitions
| Acquired company | TMO:NYQ since announced | Transaction value |
|---|---|---|
| Clario Inc | -8.88% | 9.40bn |
| Sanofi SA-Steriles Manufacturing Site | 21.56% | -- |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Becton Dickinson and Co | 21.92bn | 1.76bn | 50.27bn | 72.00k | 28.48 | 1.96 | 11.74 | 2.26 | 6.12 | 6.12 | 76.34 | 88.79 | 0.4004 | 2.96 | 8.52 | 304,500.00 | 3.21 | 3.00 | 3.78 | 3.48 | 46.42 | 45.58 | 8.01 | 8.20 | 0.5826 | 6.68 | 0.4359 | 66.89 | 8.24 | 6.32 | -1.58 | 46.93 | -0.2352 | 5.65 |
| Edwards Lifesciences Corp | 6.07bn | 1.06bn | 50.63bn | 16.00k | 47.21 | 4.79 | 40.85 | 8.16 | 1.81 | 1.83 | 10.36 | 17.80 | 0.4536 | 1.21 | 9.57 | 379,225.00 | 7.89 | 13.08 | 9.04 | 14.96 | 78.01 | 79.39 | 17.40 | 24.79 | 3.09 | -- | 0.0547 | 0.00 | 11.55 | 6.70 | -24.33 | 5.18 | -8.57 | -- |
| IDEXX Laboratories Inc | 4.30bn | 1.06bn | 50.70bn | 11.00k | 48.59 | 31.56 | 42.01 | 11.76 | 13.08 | 13.08 | 53.12 | 20.14 | 1.30 | 4.33 | 7.40 | 391,245.60 | 31.89 | 28.96 | 47.86 | 43.58 | 61.80 | 60.30 | 24.62 | 22.86 | 0.9019 | 37.97 | 0.3456 | 0.00 | 10.42 | 9.72 | 19.33 | 12.74 | 5.08 | -- |
| Medline Inc | 28.43bn | 1.16bn | 60.23bn | 45.00k | 50.32 | 5.43 | 28.84 | 2.05 | 0.8822 | 0.8822 | 21.64 | 8.17 | -- | -- | -- | 631,822.30 | -- | -- | -- | -- | 26.44 | -- | 4.07 | -- | 2.37 | 2.59 | 0.3944 | -- | 11.47 | -- | -3.42 | -- | -- | -- |
| Cencora Inc | 325.78bn | 1.63bn | 72.49bn | 51.00k | 44.68 | 37.86 | 26.85 | 0.2218 | 8.31 | 8.31 | 1,671.64 | 9.81 | 4.42 | 14.08 | 12.21 | 6,387,800.00 | 2.23 | 2.64 | 9.81 | 11.63 | 3.63 | 3.38 | 0.5035 | 0.6038 | 0.5086 | 11.82 | 0.7908 | 24.98 | 9.31 | 11.09 | 2.99 | -- | 12.56 | 5.79 |
| Boston Scientific Corp | 20.08bn | 2.90bn | 113.10bn | 59.00k | 38.08 | 4.52 | 25.72 | 5.46 | 1.94 | 1.94 | 13.43 | 16.34 | 0.4833 | 2.16 | 7.32 | 340,254.30 | 6.97 | 4.57 | 8.18 | 5.31 | 69.01 | 69.07 | 14.41 | 10.67 | 1.08 | 12.50 | 0.3185 | 0.00 | 19.87 | 15.16 | 56.40 | -- | 10.91 | -- |
| Medtronic PLC | 35.48bn | 4.61bn | 125.95bn | 95.00k | 27.01 | 2.53 | 16.08 | 3.50 | 3.58 | 3.58 | 27.55 | 38.17 | 0.3911 | 2.07 | 5.69 | 373,505.30 | 5.12 | 4.55 | 5.81 | 5.15 | 65.16 | 66.25 | 13.08 | 13.07 | 1.87 | 8.53 | 0.3633 | 84.20 | 3.62 | 3.01 | 26.82 | -0.2723 | 8.91 | 5.33 |
| Danaher Corp | 24.57bn | 3.60bn | 145.67bn | 58.00k | 40.54 | 2.75 | 23.86 | 5.87 | 5.03 | 5.05 | 34.31 | 74.32 | 0.3052 | 4.16 | 6.60 | 423,586.20 | 4.47 | 5.74 | 4.89 | 6.34 | 59.23 | 59.98 | 14.65 | 18.98 | 1.51 | 10.87 | 0.2596 | 16.35 | 2.90 | 1.97 | -7.67 | 0.5076 | 7.88 | 12.51 |
| Stryker Corp | 25.12bn | 3.25bn | 148.11bn | 56.00k | 45.79 | 6.56 | 33.16 | 5.86 | 8.40 | 8.40 | 64.98 | 58.61 | 0.5531 | 1.76 | 6.26 | 448,500.00 | 7.15 | 7.04 | 8.61 | 8.46 | 64.57 | 64.06 | 12.92 | 13.26 | 1.21 | 11.73 | 0.4143 | 41.77 | 11.16 | 11.84 | 8.45 | 15.21 | 9.34 | 3.02 |
| Intuitive Surgical Inc | 10.06bn | 2.86bn | 176.23bn | 17.02k | 63.15 | 9.91 | 49.71 | 17.55 | 7.88 | 7.88 | 27.75 | 50.19 | 0.5135 | 2.06 | 7.31 | 591,310.80 | 14.68 | 13.20 | 16.33 | 14.71 | 66.00 | 67.14 | 28.58 | 26.96 | 3.96 | -- | 0.00 | 0.00 | 20.51 | 18.22 | 22.97 | 21.91 | 9.59 | -- |
| Thermo Fisher Scientific Inc | 44.56bn | 6.70bn | 188.93bn | 125.00k | 28.67 | 3.58 | 19.78 | 4.24 | 17.72 | 17.72 | 117.80 | 141.96 | 0.4291 | 5.06 | 4.41 | 356,448.00 | 6.51 | 7.12 | 7.56 | 8.36 | 40.93 | 42.74 | 15.17 | 15.87 | 1.53 | 19.63 | 0.4239 | 7.91 | 3.91 | 6.70 | 5.82 | 1.01 | 0.6826 | 15.14 |
| Abbott Laboratories | 44.33bn | 6.52bn | 198.30bn | 115.00k | 30.44 | 3.78 | 20.48 | 4.45 | 3.73 | 3.73 | 25.36 | 30.02 | 0.5273 | 3.03 | 5.97 | 385,460.90 | 7.76 | 10.33 | 9.55 | 12.72 | 56.66 | 56.20 | 14.72 | 18.61 | 1.18 | 61.89 | 0.1968 | 46.20 | 5.67 | 5.08 | -51.32 | 7.73 | -0.0552 | 10.76 |
Data as of Mar 03 2026. Currency figures normalised to Thermo Fisher Scientific Inc's reporting currency: US Dollar USD
29.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 30.43m | 8.10% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 17.49m | 4.66% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 16.61m | 4.42% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2025 | 11.00m | 2.93% |
| Geode Capital Management LLCas of 31 Dec 2025 | 8.20m | 2.18% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Dec 2025 | 7.14m | 1.90% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 6.82m | 1.81% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 5.74m | 1.53% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 5.30m | 1.41% |
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2025 | 3.76m | 1.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
